Literature DB >> 22230249

VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression.

Haibo Wang1, Grace Byfield2, Yanchao Jiang1, George Wesley Smith1, Manabu McCloskey1, M Elizabeth Hartnett3.   

Abstract

Avascular, hypoxic retina has been postulated to be a source of angiogenic factors that cause aberrant angiogenesis and intravitreal neovascularization (IVNV) in retinopathy of prematurity. Vascular endothelial growth factor (VEGF) is an important factor involved. However, VEGF is also required for normal retinal vascular development, which raises concerns about inhibiting its activity to treat IVNV in retinopathy of prematurity. Therefore, understanding the effects that VEGF has on other factors in the development of avascular retina is important to prevent aberrant angiogenesis and IVNV. Here, we show that STAT3 was activated by increased retinal VEGF in the rat 50/10 oxygen-induced retinopathy model. Phospho-STAT3 colocalized with glutamine synthetase-labeled Müller cells. Inhibition of STAT3 reduced avascular retina and increased retinal erythropoietin (Epo) expression. Epo administered exogenously also reduced avascular retina in the model. In an in vitro study, hypoxia-induced VEGF inhibited Epo gene expression by STAT3 activation in rat Müller cells. The mechanism by which activated STAT3 regulated Epo was by inhibition of Epo promoter activity. Together, these findings show that increased retinal VEGF contributes to avascular retina by regulating retinal Epo expression through Janus kinase/STAT signaling. Our results suggest that rescuing Epo expression in the retina before the development of IVNV may promote normal developmental angiogenesis and, therefore, reduce the stimulus for later pathologic IVNV. Copyright Â
© 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230249      PMCID: PMC3349887          DOI: 10.1016/j.ajpath.2011.11.031

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  VEGF differentially activates STAT3 in microvascular endothelial cells.

Authors:  Manuela Bartoli; Dan Platt; Tahira Lemtalsi; Xiaolin Gu; Steven E Brooks; Mario B Marrero; Ruth B Caldwell
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191

2.  Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy.

Authors:  H Sone; Y Kawakami; T Segawa; Y Okuda; Y Sekine; S Honmura; T Segawa; H Suzuki; K Yamashita; N Yamada
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

3.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.

Authors:  N Meydan; T Grunberger; H Dadi; M Shahar; E Arpaia; Z Lapidot; J S Leeder; M Freedman; A Cohen; A Gazit; A Levitzki; C M Roifman
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

Review 4.  Retinopathy of prematurity.

Authors:  Jing Chen; Lois E H Smith
Journal:  Angiogenesis       Date:  2007-02-27       Impact factor: 9.596

5.  Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.

Authors:  Jing Chen; Kip M Connor; Christopher M Aderman; Keirnan L Willett; Oskar P Aspegren; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

6.  Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.

Authors:  Steven Budd; Grace Byfield; David Martiniuk; Pete Geisen; Mary Elizabeth Hartnett
Journal:  Exp Eye Res       Date:  2009-07-01       Impact factor: 3.467

7.  Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation.

Authors:  Yoko Yahata; Yuji Shirakata; Sho Tokumaru; Kenshi Yamasaki; Koji Sayama; Yasushi Hanakawa; Michael Detmar; Koji Hashimoto
Journal:  J Biol Chem       Date:  2003-07-21       Impact factor: 5.157

8.  Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.

Authors:  Helen A Mintz-Hittner; Ronald R Kuffel
Journal:  Retina       Date:  2008-06       Impact factor: 4.256

9.  IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth.

Authors:  Chatarina Lofqvist; Jing Chen; Kip M Connor; Alexandra C H Smith; Christopher M Aderman; Nan Liu; John E Pintar; Thomas Ludwig; Ann Hellstrom; Lois E H Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-13       Impact factor: 11.205

10.  The effect of oxygen on vasoformative cell division. Evidence that 'physiological hypoxia' is the stimulus for normal retinal vasculogenesis.

Authors:  T Chan-Ling; B Gock; J Stone
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-06       Impact factor: 4.799

View more
  27 in total

1.  VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis.

Authors:  Zhihong Yang; Haibo Wang; Yanchao Jiang; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2014-03-12       Impact factor: 4.307

2.  Assessment of vascular regeneration in the CNS using the mouse retina.

Authors:  Khalil Miloudi; Agnieszka Dejda; François Binet; Eric Lapalme; Agustin Cerani; Przemyslaw Sapieha
Journal:  J Vis Exp       Date:  2014-06-23       Impact factor: 1.355

3.  STAT3 Protein Regulates Vascular Smooth Muscle Cell Phenotypic Switch by Interaction with Myocardin.

Authors:  Xing-Hua Liao; Nan Wang; Dong-Wei Zhao; De-Liang Zheng; Li Zheng; Wen-Jing Xing; Wen-Jian Ma; Le-Yuan Bao; Jian Dong; Tong-Cun Zhang
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

4.  Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human.

Authors:  Ugur Acar; Bekir Kucuk; Mehmet Koray Sevinc; Seckin Aykas; Mesut Erdurmus; Gungor Sobaci
Journal:  Int Ophthalmol       Date:  2017-05-19       Impact factor: 2.031

Review 5.  Pathophysiology and mechanisms of severe retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Ophthalmology       Date:  2014-10-14       Impact factor: 12.079

6.  Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity.

Authors:  Manabu McCloskey; Haibo Wang; Yanchao Jiang; George Wesley Smith; Jeremy Strange; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-21       Impact factor: 4.799

7.  Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.

Authors:  Haibo Wang; Zhihong Yang; Yanchao Jiang; John Flannery; Scott Hammond; Tal Kafri; Sai Karthik Vemuri; Bryan Jones; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-04       Impact factor: 4.799

8.  Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.

Authors:  Yanchao Jiang; Haibo Wang; David Culp; Zhihong Yang; Lori Fotheringham; John Flannery; Scott Hammond; Tal Kafri; M Elizabeth Hartnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-10       Impact factor: 4.799

9.  STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells.

Authors:  M R Pawlus; L Wang; C-J Hu
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

10.  Histone demethylase KDM4C activates HIF1α/VEGFA signaling through the costimulatory factor STAT3 in NSCLC.

Authors:  Xiaowei Wu; Yu Deng; Yukun Zu; Jin Yin
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.